NAPROXEN SODIUM TABLETS
Country: Կանադա
language: անգլերեն
source: Health Canada
SPC
(SPC)
31-01-2012
documentation_request_body
documentation_request_send
documentation_request_send
active_ingredient:
NAPROXEN SODIUM
MAH:
VITA HEALTH PRODUCTS INC
ATC_code:
M01AE02
INN:
NAPROXEN
dosage:
220MG
pharmaceutical_form:
TABLET
composition:
NAPROXEN SODIUM 220MG
administration_route:
ORAL
units_in_package:
24/100/250/500
prescription_type:
OTC
therapeutic_area:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
leaflet_short:
Active ingredient group (AIG) number: 0113934003; AHFS:
authorization_status:
APPROVED
authorization_date:
2012-01-30
SPC
_Page 1 of 35_
PRODUCT MONOGRAPH
NAPROXEN SODIUM TABLETS
NAPROXEN SODIUM CAPLETS
NAPROXEN SODIUM TABLETS USP, 220 MG
Non-steroidal anti-inflammatory drug
Analgesic, Antipyretic
Vita Health Products Inc.
150 Beghin Avenue, Winnipeg
Manitoba, Canada R2J 3W2
Date of Preparation:
January 26, 2012
Control No.: 134246
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.............................................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................................
9
DOSAGE AND ADMINISTRATION
...................................................................................................11
OVERDOSAGE
.....................................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................12
STORAGE AND STABILITY
...............................................................................................................13
SPECIAL HANDLING INSTRUCTIONS
............................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................................14
PART II:
read_full_document
